Navigation Links
Thermo Fisher Scientific Introduces Breakthrough in RNA-Interference Technology

Accell siRNA Simplifies Delivery to Cells and Significantly Improves

Effectiveness of RNAi in Key Life Sciences Applications

WALTHAM, Mass., March 10 /PRNewswire-FirstCall/ -- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, has developed a breakthrough gene-silencing tool that greatly simplifies RNA- interference (RNAi) technology and eliminates barriers associated with previous cellular delivery methods. The advance is expected to accelerate research and drug discovery in many important life sciences fields, including neuroscience, immunology, stem-cell science and oncology.

Thermo Scientific Dharmacon Accell(TM) siRNA is a novel form of short- interfering RNA (siRNA) that is absorbed directly by cells without the use of conventional delivery methods such as transfection reagents, viruses or electroporation. Dharmacon Accell siRNA effectively silences genes in all cell types tested to date.

RNAi is a powerful technology used to silence, or knock down, target genes and the proteins they produce, revealing their role in biological pathways and disease processes. Understanding gene function is critical for the development of drugs targeting those genes.

"Previous technologies for delivering siRNA into difficult cell types, such as primary cells, suspension cells, stem cells and neurons, were often ineffective and resulted in high levels of cell death," said Dr. Ian Jardine, vice president of global research and development for Thermo Fisher Scientific. "Dharmacon Accell is the only siRNA molecule that has been able to penetrate every cell type we have tested -- without the need for delivery reagents that can skew experimental results. With Dharmacon Accell siRNA and our Dharmacon SMARTvector shRNA advancement, scientists now have an effective RNAi tool set for biomedical and pharmaceutical research that will have broad implications for human health."

Dharmacon Accell siRNA is simply mixed with the optimized Accell delivery media, then added to cultured cells. It is an easy two-step process that saves researchers significant time in their laboratories and avoids the experimental variability caused by toxicity and off-target effects of conventional siRNA delivery methods.

"There is often a narrow window of conditions in which conventional siRNA delivery is effective. Dharmacon Accell siRNA achieves highly efficient siRNA delivery for gene silencing without the need for optimization," explained Jardine. "In addition, the elimination of delivery reagents, along with the associated non-specific effects, greatly simplifies the interpretation of RNAi experiments."

Preliminary studies also suggest that long-term silencing of up to 30 days can now be achieved through repeated application of Dharmacon Accell siRNA -- previously not possible with conventional synthetic siRNA reagents.

Visit to purchase, or for more information on Thermo Scientific Dharmacon Accell siRNA.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, enabling our customers to make the world healthier, cleaner and safer. With annual revenues of $10 billion, we have more than 30,000 employees and serve over 350,000 customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as environmental and industrial process control settings. Serving customers through two premier brands, Thermo Scientific and Fisher Scientific, we help solve analytical challenges from routine testing to complex research and discovery. Thermo Scientific offers customers a complete range of high-end analytical instruments as well as laboratory equipment, software, services, consumables and reagents to enable integrated laboratory workflow solutions. Fisher Scientific provides a complete portfolio of laboratory equipment, chemicals, supplies and services used in healthcare, scientific research, safety and education. Together, we offer the most convenient purchasing options to customers and continuously advance our technologies to accelerate the pace of scientific discovery, enhance value for customers and fuel growth for shareholders and employees alike. Visit

Media Contact Information: Investor Contact Information:

Lori Gorski Ken Apicerno

Phone: 781-622-1242 Phone: 781-622-1111

E-mail: E-mail:


SOURCE Thermo Fisher Scientific Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Thermo Fisher Scientific Advances Gene-Silencing Technology for Life Sciences Research
2. Life Recovery Systems Receives European CE Mark Approval for Its ThermoSuit(R) System
3. Industry Executives Finding Value in Shift of Scientific Publications
4. Childrens Mental Focus Foundation Announces a Scientific Breakthrough for Children Who Have Been Diagnosed With Autism, ADD and ADHD
5. Molecular Biometrics Hires Denny Sakkas, PhD Renowned Yale Embryologist and International Thought-Leader, as Chief Scientific Officer; Opening U.S. Research Facility
6. Boston Scientific Announces CE Mark Approval for New Devices to Treat Heart Failure and Sudden Cardiac Death
7. Second Thoughts about Fluoride, Reports Scientific American
8. XTL Biopharmaceuticals Presents Data Regarding its Hepatitis C Virus Small Molecule Program at Hep Dart 2007 - an International Scientific Conference on Viral Hepatitis
9. Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions
10. Data Presented at the American Heart Association Scientific Sessions 2007 Demonstrated Increased HDL with ACTOS(R) (pioglitazone HCl) Slowed the Progression of Carotid Intima-Media Thickness in Patients with Type 2 Diabetes
11. New Risk Factor for Heart Disease Identified in Very Young Children, According to Study at American Heart Association Scientific Sessions
Post Your Comments:
(Date:11/26/2015)... Nov. 26, 2015 Research and Markets ... the "2016 Future Horizons and Growth Strategies ... Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Emerging ... --> --> This ... the Italian therapeutic drug monitoring market, including emerging ...
(Date:11/25/2015)... , Nov. 25, 2015  Amgen (NASDAQ: AMGN ... Application (BLA) with the United States ... 501, a biosimilar candidate to Humira ® (adalimumab). ... application submitted to the FDA and represents Amgen,s first ... Sean E. Harper , M.D., executive vice president of ...
(Date:11/25/2015)... Nov. 25, 2015  ARKRAY USA ... to provide evidence demonstrating the accuracy of its blood ... on Insulin Resistance, Diabetes and Cardiovascular Disease in ... the Company,s GLUCOCARD ® 01 meter and the ... requirements. The ability to accurately measure glucose levels in ...
Breaking Medicine Technology:
(Date:11/28/2015)... ... , ... Safe storage for contraceptive devices may not always be easy to ... and the other from Bradley Beach, New Jersey, there is an easy solution to ... to replace NuvaRings more often than necessary. As such, it affords peace of mind ...
(Date:11/27/2015)... ... November 28, 2015 , ... There is only one major question facing ... last year? , This question has not been an easy question to answer. Especially ... age and the younger workforce don’t share the same discipline around working long hours. ...
(Date:11/27/2015)... ... 27, 2015 , ... The rapid speed at which Americans ... more care is needed, especially with Alzheimer’s, dementia and other cognitive conditions becoming ... The forgotten part of this equation: 80 percent of medical care occurs in ...
(Date:11/27/2015)... ... 27, 2015 , ... Lizzie’s Lice Pickers just announced a special promotion that ... of their purchase of lice treatment product. In addition, customers will receive a complimentary ... spokesperson. “Finding lice is a sure way to ruin the holidays, so we encourage ...
(Date:11/27/2015)... , ... November 27, 2015 , ... ... of progress through sharing, the 2016 Building Better Radiology Marketing Programs ... will begin on Sunday, March 6, 2016, at Caesars Palace in Las Vegas ...
Breaking Medicine News(10 mins):